GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (STU:19KA) » Definitions » Institutional Ownership

Cormedix (STU:19KA) Institutional Ownership : 19.15% (As of Jun. 10, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cormedix Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cormedix's institutional ownership is 19.15%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cormedix's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cormedix's Float Percentage Of Total Shares Outstanding is 99.95%.


Cormedix Institutional Ownership Historical Data

The historical data trend for Cormedix's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix Institutional Ownership Chart

Cormedix Historical Data

The historical data trend for Cormedix can be seen below:

2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31
Institutional Ownership 18.45 20.13 18.10 18.48 19.13 19.09 19.02 19.27 19.20 19.15

Cormedix Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cormedix (STU:19KA) Business Description

Traded in Other Exchanges
Address
300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.

Cormedix (STU:19KA) Headlines

No Headlines